glp 1 psoriatic arthritis GLP-1 therapy shows promise in treatment | UT Southwestern Department of Dermatology posted on the topic Which PsO Patients Can Benefit

Dose escalation, which is standard practice with most GLP-1 medications, helps to optimise therapeutic effects whilst minimising gastrointestinal side effects

Bond JA, Harkema JR, Russell VI

Upon activation, phosphorylated MLKL (p-MLKL) oligomerizes and translocates to the cell membrane, forming pores that disrupt electrochemical gradients, resulting in lytic cell rupture and the release of damage-associated molecular patterns (DAMPs), inflammatory cytokines and chemokines

With controlled dosages that follow recommendations, glutathione causes no adverse effects

At present, a large-scale phase III RCT of 2-year exenatide treatment in patients with PD, defined as a Hoen and Yahr (H&Y) stage of 2.5, is ongoing

F., Fernandes, P